392 related articles for article (PubMed ID: 8954183)
1. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
[TBL] [Abstract][Full Text] [Related]
2. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
[TBL] [Abstract][Full Text] [Related]
3. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
6. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
8. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
Seidman AD; Scher HI; Gabrilove JL; Bajorin DF; Motzer RJ; O'Dell M; Curley T; Dershaw DD; Quinlivan S; Tao Y
J Clin Oncol; 1993 Mar; 11(3):408-14. PubMed ID: 7680373
[TBL] [Abstract][Full Text] [Related]
9. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
11. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: long term results of a pilot study.
Vikram B; Chadha M; Malamud SC; Hecht H; Grabstald H
Cancer; 1998 Mar; 82(5):918-22. PubMed ID: 9486582
[TBL] [Abstract][Full Text] [Related]
12. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
[TBL] [Abstract][Full Text] [Related]
13. [Polychemotherapy in advanced bladder cancer. Practicality and clinical results].
Klän R; Knispel H; Huland H
Urologe A; 1992 Jul; 31(4):247-50. PubMed ID: 1514213
[TBL] [Abstract][Full Text] [Related]
14. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
Bamias A; Aravantinos G; Deliveliotis C; Bafaloukos D; Kalofonos C; Xiros N; Zervas A; Mitropoulos D; Samantas E; Pectasides D; Papakostas P; Gika D; Kourousis C; Koutras A; Papadimitriou C; Bamias C; Kosmidis P; Dimopoulos MA;
J Clin Oncol; 2004 Jan; 22(2):220-8. PubMed ID: 14665607
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D
Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565
[TBL] [Abstract][Full Text] [Related]
18. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
